Merck & Co (MRK)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data across its HIV treatment and prevention pipeline and portfolio will be presented at HIV Drug Therapy Glasgow 2026 (HIV Glasgow 2026), taking place Nov 8–11, 2026, in Glasgow, Scotland. Presentations will highlight Merck’s strategy to expand oral options in both HIV treatment and prevention, including data on once-daily IDVYNSO® (doravirine/islatravir), the investigational once-weekly oral treatment regimens islatravir/lenacapavir (ISL/LEN) and islatravir/ulonivirine (ISL/ULO), and the investigational once-monthly oral pre-exposure prophylaxis (PrEP) alimatravir (AMI, MK-8527).

Investors who lost money on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Merck & Co., Inc.

Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the Company may have violated the federal securities laws. The investigation comes after an October 22, 2026 disclosure concerning Merck & Co., Inc.

Merck & Co., Inc. ("Merck" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Merck & Co., Inc. (NYSE: MRK), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Merck & Co., Inc. on October 22, 2026.

Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2026.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 KEYNOTE‑C93 trial, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence after receiving prior adjuvant therapy. Results showed KEYTRUDA as monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) for these patients, reducing the risk of disease progression or death by 43% (HR=0.57; [95% CI, 0.42-0.79]; p=0.0002) compared to platinum doublet chemotherapy. These late-breaking results will be presented today during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 [Presentation #LBA12], were selected for an official ESMO press briefing and were published simultaneously in The Lancet.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) being developed in collaboration with Kelun-Biotech, in patients with advanced or recurrent endometrial cancer who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy. At a pre-specified interim analysis, the study demonstrated statistically significant and clinically meaningful improvement in its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) as well as its key secondary endpoint of objective response rate (ORR) compared with treatment of physician’s choice (TPC; doxorubicin or paclitaxel). TroFuse-005 is the first global Phase 3 trial and the first ADC to demonstrate statistically significant improvement in both OS and PFS compared to chemotherapy for these patients with advanced or recurrent endometrial cancer. These late-breaking data will be presented for the first time today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2026 [Presentation #LBA11], were selected for an official ESMO press briefing, and were published simultaneously in The Lancet.

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as adjuvant treatment for patients with completely resected stage IIB-IV melanoma. These late-breaking results will be presented for the first time during Presidential Symposium I at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation #LBA1), were selected for an official ESMO Press Briefing and have been accepted for publication in The New England Journal of Medicine.

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.

EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invasive bladder cancer (MIBC). This approval, which also covers KEYTRUDA SC® [known as KEYTRUDA QLEXTM (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.], marks the first and only PD-1 inhibitor plus antibody-drug conjugate (ADC) regimen available for patients with MIBC regardless of cisplatin eligibility in the European Union (EU).

Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Paul J. Diaz, managing partner at Cressey & Company, will join the Company’s Board of Directors effective Nov. 1, 2026. He will stand for election by the company’s shareholders in May 2027. With the addition of Mr. Diaz, the Merck board will consist of 14 members.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential Symposia at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain from Oct. 23-27. Additionally, more than 90 additional abstracts across more than 20 tumor types from the company’s pipeline and portfolio will be presented throughout the meeting.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting in New Orleans: BRUNELLO - 1-Year Pivotal Trial Results of Remigromig (MK-3000, formerly EYE103) for the Treatment of Diabetic Macular Edema; D. D'Amico.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2026 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 29. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS). These data will be presented in a Late-Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2026 Congress (Abstract ID: LB-26).

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of WELIREG® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, which is involved in the repair and maintenance of the blood-retinal-barrier.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial. WINREVAIR, an activin signaling inhibitor, is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class (FC), and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death. Today’s approval updates the WINREVAIR label to include efficacy and safety data from the HYPERION trial evaluating adults newly diagnosed with PAH (WHO FC II or III, diagnosed within 12 months of study screening) at intermediate to high risk of disease progression, providing insights into the role of WINREVAIR when added to background therapy within the first year of a PAH diagnosis.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous use for all indications approved in Japan for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. In Japan, KEYJECT®, for subcutaneous injection is the planned trademark for KEYTRUDA QLEX. KEYJECT can be administered in one minute every three weeks or in two minutes every six weeks. Berahyaluronidase alfa is a variant of hyaluronidase developed and manufactured by Alteogen Inc. For a list of select indications for which KEYTRUDA and KEYTRUDA QLEX are approved in the United States, see Selected Indications in the U.S. below.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adults with resectable muscle-invasive bladder cancer (MIBC). This recommendation, which also includes KEYTRUDA SC® [known as KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in the U.S.], will now be reviewed by the European Commission (EC) for marketing authorization in the European Union (EU), Iceland, Liechtenstein and Norway. A final decision is expected by the fourth quarter of 2026.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today launched Your Hive of Whole Health, a multi-year educational program that helps people living with HIV build personalized networks of support to address their physical, mental, emotional, and social well-being. Unveiled at the 2026 U.S. Conference on HIV/AIDS (USCHA) in Anaheim, California, Sept. 17-20, 2026, the initiative aims to honor the strides made toward ending the epidemic while emphasizing that future progress depends on a collective focus on whole person health.

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.